24 Multicenter validation study of a novel StripAssay for cystic fibrosis  by Puehringer, H. et al.
2. Screening & Diagnosis S7
24 Multicenter validation study of a novel StripAssay for cystic
ﬁbrosis
H. Puehringer1, M. Macek Jr.2, A. Stambergova2, L. Dvorakova2, M. Dunø3,
B. Tuemmler4, S. Hedtfeld4, M. Tzetis5, M. Poulou5, C. Oberkanins1. 1ViennaLab
Diagnostics GmbH, Vienna, Austria; 2Charles University, Department of Biology
and Medical Genetics, Prague, Czech Republic; 3University Hospital, Department
of Clinical Genetics, Copenhagen, Denmark; 4Hannover Medical School,
Department of Pediatrics, Hannover, Germany; 5National Kapodistrian University,
Department of Medical Genetics, Athens, Greece
Cystic ﬁbrosis (CF), with an incidence of approximately 1 in 3000 live births
in Caucasians, is caused by mutations in the cystic-ﬁbrosis transmembrane con-
ductance regulator (CFTR) gene. To date, more than 1500 CFTR mutations have
been described, the majority being very rare or private. Worldwide, the most
frequent mutation F508del accounts for 30−72% of CF chromosomes depending
upon ethnicity. Overall there is great heterogeneity in the remaining pathogenic
mutations, as type and distribution vary substantially between populations.
We have developed a reverse-hybridization assay for the rapid and simultaneous
analysis of 23 CFTR mutations recommended by the ACMG plus 10 additional
ones prevalent in different parts of Europe, as well as the IVS8 polyT (5T/7T/9T)
variants. The CF StripAssay, showing a coverage of 70−93% almost all over Europe,
is rapid, simple and accessible to automation. The test requires very small amounts
of samples, which is of particular importance for prenatal diagnosis and newborn
screening. In the ﬁrst phase of a multicenter validation study genotyping results
from 96 out of 111 (86.5%) previously tested samples were conﬁrmed by the
CF StripAssay. The remaining discrepant genotypes were due to missing mutant
probes on the teststrips. Currently the assay is validated prospectively under routine
diagnostic settings in the participating centers.
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Introduction: The potential advantages of Luminex xTAG 71 mutations v2 test,
in replacement to the INNO-LiPA CFTR19 + CFTR17+Tn kit, for routine CFTR
screening were evaluated.
Results: 1350 DNA samples were processed for CFTR diagnosis at our university
lab. Samples were recruited from the fertility program, the paediatric pulmonology
and gastro-intestinal departments. Globally, 114 samples (8.4%) displayed at least
one CFTR causing mutation. Of these, 5 distinct mutations (L260W; R75Q;
Y1092X; R347H; 3120+1G>A) could exclusively be picked up by Luminex; they
were conﬁrmed by direct sequencing. L206W was detected from two subjects: in one
of them, suffering from idiopathic pancreatitis, S1235R was detected by full exon
sequencing; no additional mutation was found in the other subject. R75Q/R75Q
was associated with pancreatitis. Y1092X was identiﬁed in a classical CF patient
also displaying F508del. R347H was found at a heterozygous status during a
preconception screening. 3120+1G>A was displayed in a neonate with elevated IRT
for whom clinical investigation is currently ongoing at our CF centre. Analyses of
the 1350 samples showed 5 polymorphisms: 4×F508C and 1× I506V.
Conclusion: The launch of the Luminex xTAG 71 mutations v2 test appears to be
extremely valuable for European cities with increasingly heterogeneous and distinct
ethnic populations. It covers more gene mutation coverage than any other currently
available routine test (71 vs 35 mutations for Luminex vs Innogenetics). An
increased (by 0.5%) detection rate, but similar cost, was revealed for Luminex which
also accurately detects the three I506V, I507V, F508C polymorphisms recommended
by the ACMG/ACOG.
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For more than half a century sweat testing has been the “gold standard” for the
diagnosis of CF. However, normal and borderline sweat chloride values are not
unanimously accepted in different parts of the world. In our country sweat testing
has been performed since 1961 and currently we have an experience with more
than 35,000 tests, which were performed at a single facility. In this respect we
analyzed sweat chloride concentration of 4,974 controls versus 252 CF patients.
Sweating was stimulated by pilocarpine iontophoresis, collected in a chloride free
ﬁlter paper and sweat chloride determination has been performed in a standardized
way using coulometric titration by means of Chloride-Titrator™ CMT 10. The
entire procedure was performed by one qualiﬁed technician. For statistical analysis
we used chi2 test and the Bayes’ method. The decomposition of our ﬁles was
logarithmic. Frequentional curves of both groups were constructed. In order to
determine the limit between normal and borderline values we used three statistical
methods: classical method minimizing the overlap area of both frequentional
curves, Bay-max method which maximized the right decisions and Bay-min that
minimized incorrect decisions. The limit values of the three methods were 28.48–
30.12–31.5mmol/L, respectively. Only 3.15% of controls exceeded the value of
31.5mmol/L and in less than 1% their chloride concentration was higher than
40mmol/L. Therefore, since 1985 all values higher than 30mmol/L are considered
as being “borderline” in our country. We will present our diagnostic strategies and
include recent conﬁrmatory results.
Supported by MZOFNM2005 and IGA NS9986−3.
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Background: Sweat testing is still the standard diagnostic method for detection of
cystic ﬁbrosis. The indication for sweat testing ranges from pulmonary, gastroin-
testinal or other more or less severe clinical ﬁndings to routine testing in newborn
screening programs. Aim of this investigation is to show, which cause led to sweat
testing in the last six years at our hospital and what was the outcome in addiction
to the cause of investigation.
Methods: Iontophoresis was done by Wescor MACRODUCT Modell 3700-SYS
for iontophoresis and sweat collection. Measurement of chloride concentration in
the sweat was done with the Kreienbaum Chloridmeter, measurement of NaCl-
Equivalent with Wescor Sweat Check.
Results: From 2006 to 2010 we did over 1000 sweat tests. In about 60% of cases
indication for testing was set from our own hospital or outpatient department. A
small number of cases was sent from other hospitals of our University like adult
medicine, ENT or psychiatry. In 10 to 15% of cases abnormal ﬁndings in cystic
ﬁbrosis newborn screening caused the sweat test investigation. Gastroenteral or
pulmonary led to sweat testing in nearly the same number of cases. In 20 children
and one adult the diagnose of cystic ﬁbrosis was conﬁrmed. In 17 of the 20 children
abnormal ﬁndings in cystic ﬁbrosis newborn screening caused the sweat testing.
Conclusion: Newborn screening is a good indicator for cystic ﬁbrosis independent
of clinical symptoms. Nevertheless patients are still sent for sweat testing due to
clinical symptoms indicating cystic ﬁbrosis, so doctors are still aware of them.
